<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00271323</url>
  </required_header>
  <id_info>
    <org_study_id>XRP6976B_2507</org_study_id>
    <secondary_id>EudraCT #: 2005-001276-12</secondary_id>
    <nct_id>NCT00271323</nct_id>
  </id_info>
  <brief_title>Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC Patients</brief_title>
  <official_title>A Two Arm Phase II Study Assessing Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in Patients With Locally Advanced Unresectable NSCLC (Stage IIIA-multiple cN2 or IIIB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Primary : To determine the safety profile of each treatment group.&#xD;
&#xD;
        -  Secondary : To determine efficacy in term of overall response, disease free survival and&#xD;
           survival at 1 and 2 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate</measure>
    <time_frame>in population of patients eligible and evaluable for response</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>time to progression</measure>
    <time_frame>from the date of start treatment until progression</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>duration of response</measure>
    <time_frame>only on responders</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Non-Small-Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction chemotherapy followed by concurrent chemoradiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Concurrent chemo-radiotherapy followed by consolidation chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel and cisplatin</intervention_name>
    <description>Docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemo-radiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>Docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy followed by docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed consent form obtained, signed and dated before specific protocol procedures.&#xD;
&#xD;
          2. Histologically or cytologically confirmed NSCLC (adenocarcinoma, squamous cell&#xD;
             carcinoma, large cell carcinoma or a combination of these)&#xD;
&#xD;
          3. Patients must have a loco regionally advanced unresectable NSCLC;&#xD;
&#xD;
               -  Stage IIIA with clinical multiple N2 nodes (preferably with histological or&#xD;
                  cytological confirmation).&#xD;
&#xD;
                    -  Patients with peripheral tumours of the lower lobe with contralateral upper&#xD;
                       mediastinal nodes at station N2 are excludedÂ·&#xD;
&#xD;
               -  Stage IIIB T4 or N3.&#xD;
&#xD;
                    -  In the T4 category, patients with pleural or pericardial effusion and&#xD;
                       multiple nodules in the same lobe are excluded.&#xD;
&#xD;
                    -  Patients with T4 disease secondary to extensive and massive involvement of&#xD;
                       the great vessels are excluded.Patients should be excluded when the expected&#xD;
                       risk of pulmonary toxicity is likely to be high, e.g. V20 in excess of 35%.&#xD;
&#xD;
          4. Males or females aged between 18 and 75 years.&#xD;
&#xD;
          5. Life expectancy of at least 12 weeks.&#xD;
&#xD;
          6. WHO performance status 0 or 1.&#xD;
&#xD;
          7. Weight loss &lt;=10% within the last 3 months.&#xD;
&#xD;
          8. Laboratory requirements at entry (within 7 days before randomization):&#xD;
&#xD;
               -  Blood cell counts:&#xD;
&#xD;
                    -  Absolute neutrophils &gt;= 2.0 x 10^9/L&#xD;
&#xD;
                    -  Platelets &gt;= 100 x 10^9/L&#xD;
&#xD;
                    -  Hemoglobin &gt;= 10 g/dl&#xD;
&#xD;
               -  Renal function:&#xD;
&#xD;
                    -  Serum creatinine &lt;=1 x the upper limit of normal (UNL). In case of&#xD;
                       borderline value of serum creatinine, the 24h creatinine clearance should be&#xD;
                       &gt;= 60 mL/min.&#xD;
&#xD;
               -  Hepatic function:&#xD;
&#xD;
                    -  Serum bilirubin &lt;= 1 x UNL&#xD;
&#xD;
                    -  ASAT and ALAT &lt;= 2.5 x UNL&#xD;
&#xD;
                    -  Alkaline phosphatase &lt;= 5 x UNL Patients with ASAT and/or ALAT &gt; 1.5 x UNL&#xD;
                       associated with alkaline phosphatase&gt; 2.5 x UNL are not eligible for the&#xD;
                       study.&#xD;
&#xD;
          9. Lung function tests at entry:&#xD;
&#xD;
               -  FEV1: &gt;= 50 % x Normal value&#xD;
&#xD;
               -  DLCO: &gt;= 50 % x Normal value&#xD;
&#xD;
         10. Adequate cardiac function.&#xD;
&#xD;
         11. Patient with either measurable and/or non-measurable lesion (according to RECIST&#xD;
             criteria).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of small cell lung cancer.&#xD;
&#xD;
          2. Pregnant or lactating women.&#xD;
&#xD;
          3. Patients (male or female) with reproductive potential not implementing adequate&#xD;
             contraceptive measures.&#xD;
&#xD;
          4. Prior systemic chemotherapy, immunotherapy, or biological therapy including&#xD;
             neoadjuvant or adjuvant treatment for NSCLC.&#xD;
&#xD;
          5. Prior surgery for NSCLC, if less than 5 years from study.&#xD;
&#xD;
          6. Prior radiotherapy for NSCLC.&#xD;
&#xD;
          7. History of prior malignancies, except for cured non-melanoma skin cancer, curatively&#xD;
             treated in-situ carcinoma of the cervix or other cancer curatively treated and with no&#xD;
             evidence of disease for at least five years.&#xD;
&#xD;
          8. Symptomatic peripheral neuropathy Grade &gt;= 2 except if due to trauma.&#xD;
&#xD;
          9. Other serious concomitant illness or medical conditions:&#xD;
&#xD;
               -  Congestive heart failure or angina pectoris except if it is medically controlled.&#xD;
                  Previous history of myocardial infarction within 1 year from study entry,&#xD;
                  uncontrolled hypertension or arrhythmias.&#xD;
&#xD;
               -  History of significant neurological or psychiatric disorders including dementia&#xD;
                  or seizures.&#xD;
&#xD;
               -  Active infection requiring IV antibiotics.&#xD;
&#xD;
               -  Active ulcer, unstable diabetes mellitus or other contra-indication to&#xD;
                  corticosteroid therapy.&#xD;
&#xD;
               -  Superior vena cava syndrome contra-indicating hydration.&#xD;
&#xD;
               -  Preexisting pericardial effusion.&#xD;
&#xD;
               -  Preexisting symptomatic pleural effusion.&#xD;
&#xD;
         10. Significant gastrointestinal abnormalities, including requirement for intravenous&#xD;
             nutrition, active peptic ulcer disease, prior surgical procedures affecting&#xD;
             absorption.&#xD;
&#xD;
         11. Distant metastasis.&#xD;
&#xD;
         12. Concurrent treatment with any other experimental anti-cancer drugs.&#xD;
&#xD;
         13. Concomitant or within 4-week period administration of any other experimental drug&#xD;
             under investigation.&#xD;
&#xD;
         14. Significant ophthalmologic abnormalities.&#xD;
&#xD;
         15. Moderate to severe dermatitis.&#xD;
&#xD;
         16. Hypersensitivity to docetaxel, cisplatin, or any of its excipients.&#xD;
&#xD;
         17. Concomitant use of phenytoin, carbamazepin, barbiturates, or rifampicin.&#xD;
&#xD;
         18. Mental condition rendering the patient unable to understand the nature, scope, and&#xD;
             possible consequences of the study.&#xD;
&#xD;
         19. Patient unlikely to comply with protocol, i.e., uncooperative attitude, inability to&#xD;
             return for follow-up visits, and not likely to complete the study.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M COUDERC, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>December 29, 2005</study_first_submitted>
  <study_first_submitted_qc>December 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2005</study_first_posted>
  <last_update_submitted>December 21, 2009</last_update_submitted>
  <last_update_submitted_qc>December 21, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2009</last_update_posted>
  <responsible_party>
    <name_title>&quot;Medical Affairs Study Director&quot;</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

